Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2089705 | 1.00 | SIGMAR1 (0.46) | SIGMAR1MC4RACHELMNABCHE | |
| SCHEMBL6726679 | 0.82 | SIGMAR1 (0.50) | SIGMAR1MC4RLMNAALDH1A1 | |
| SCHEMBL2089277 | 0.81 | SIGMAR1 (0.53) | SIGMAR1MC4RACHELMNABCHE | |
| Hydrochloric Acid SCHEMBL29257059 | 0.80 | SIGMAR1 (0.52) | SIGMAR1MC4RLMNAPOLBALDH1A1 | |
| SCHEMBL4292791 | 0.80 | SIGMAR1 (0.52) | SIGMAR1MC4RACHELMNABCHE | |
| SCHEMBL4842229 | 0.80 | SIGMAR1 (0.52) | SIGMAR1MC4RACHELMNABCHE | |
| SCHEMBL4836946 | 0.80 | SIGMAR1 (0.52) | SIGMAR1MC4RACHELMNABCHE | |
| SCHEMBL7240008 | 0.80 | SIGMAR1 (0.52) | SIGMAR1MC4RACHELMNABCHE | |
| SCHEMBL27798980 | 0.77 | SIGMAR1 (0.49) | SIGMAR1MC4RACHELMNAPOLB | |
| SCHEMBL5563432 | 0.76 | SIGMAR1 (0.47) | SIGMAR1ACHELMNABCHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329908-B2 | Dual action antibiotics | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2012-12-11 | — | — | US | disclosed |
| US-20110059946-A1 | DUAL ACTION ANTIBIOTICS | MORPHOCHEM AKTIENGESELLSCHAFT FUER KOMBINATORISCHE CHEMIE (DE) | 2011-03-10 | — | — | US | disclosed |
| US-7820823-B2 | Dual action antibiotics | Morphochem Aktiengesellschaft Fur Kominatorische Chemi (DE) | 2010-10-26 | — | — | US | disclosed |
| US-20050096343-A1 | Dual action antibiotics | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2005-05-05 | — | — | US | disclosed |
| EP-1432705-A2 | DUAL ACTION ANTIBIOTICS | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003032962-A2 | DUAL ACTION ANTIBIOTICS | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2003-04-24 | — | — | WO | disclosed |
| WO-2003031443-A1 | DUAL ACTIONS ANTIBIOTICS COMPRISING A OXAZOLDINONE AND A QUINOLONE OR NAPHTHYRIDINONE MOIETY | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2003-04-17 | — | — | WO | disclosed |
| WO-2003031441-A1 | MULTIPLE ACTION COMPOUNDS | MORPHOCHEN AKTIENGESELLSCHAFT FÜR KOMBINATORISCHE CHEMIE (DE) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096343-A1 | Dual action antibiotics | SLC11A2, MRPL21, MAP2K5 | SIGMAR1 1702/4885MC4R 4084/4885ACHE 4348/4885 |
| US-20110059946-A1 | DUAL ACTION ANTIBIOTICS | SLC11A2, MRPL21, MAP2K5 | SIGMAR1 1314/4885MC4R 4289/4885ACHE 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.